Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.

Carrie M HershArman AltincatalNicholas BelvisoShivani KapadiaCarl de MoorRichard RudickJames Rhys WilliamsCatherine MillerIrene Koulinska

Published in: Multiple sclerosis journal - experimental, translational and clinical (2022)

In this study, DMF and FTY demonstrated similar effects on physical and cognitive neuroperformance and MRI outcomes. Direct comparisons to other fumarates and S1P receptor modulators were not conducted.

Keyphrases

multiple sclerosis
randomized controlled trial
magnetic resonance imaging
small molecule
systematic review
physical activity
mental health
contrast enhanced
high resolution
magnetic resonance
diffusion weighted imaging
adipose tissue
mass spectrometry
insulin resistance
skeletal muscle